Business Wire

Murata HCR Redefines Automotive Timing Devices With the Total Frequency Tolerance of ±40PPM Under -40°C to +125°C Operation

Share

Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) unveils a cutting-edge electronic timing device featuring exceptional accuracy ±40ppm and reliability even in wide-temperature -40°C to +125°C conditions. By addressing the limitations of current timing components in automotive electronic systems, it enhances the design and deployment of next-generation In-Vehicle Networks (IVN), wireless communication, and Advanced Driver Assistance Systems (ADAS) functions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113670074/en/

Murata Manufacturing Co., Ltd.: The new Timing Devices, XRCGE_M_F series (Photo: Business Wire)

As the automotive industry continues to pursue greater integration and electronic downsizing to address the expanding number of critical electronic systems, the performance requirements for components are growing. In order to achieve tighter packaging without compromising accuracy, it is now necessary for critical components like timing devices to have higher temperature limits. There is also a growing demand to incorporate features like Bluetooth® Low Energy (BLE) and ethernet in vehicles, which demands more accurate timing than what is typically offered by automotive crystal units.

Murata’s high accuracy and high temp automotive crystal (HCR), or XRCGE_M_F series, redefines timing component performance and reliability. It sets a new global standard as the first of its kind to achieve a total frequency tolerance of ±40 ppm throughout an operating temperature range of -40°C to +125°C. This combination allows automotive engineers to achieve the stable and highly accurate timing without the need for system calibration or temperature compensation measures, reducing development efforts and costs.

Murata has a long-standing history of being at the forefront of automotive timing solutions, starting with the introduction of its ceramic resonators in 1997 and followed by its crystal units in 2015 – HCR is the next step. Through the optimization of artificial crystal growth, assembly, and inspection, Murata’s groundbreaking resin-sealed package technology, along with the optimization of crystal design, allows HCR to achieve high-temperature operation and high accuracy. This combination is perfectly suited to support the latest vehicle communication and safety functions such as CAN and ethernet IVNs, ADAS components like cameras, LIDAR, and RADAR, as well as wireless communication technologies such as RF, NFC, BLE, ZigbeeTM, and UWB.

“HCR is a true step forward that perfectly aligns with the latest automotive demands,” said Munenori Hikita, Director of Functional Devices Division at Murata. “With our ‘world’s first’ solution, engineers will be able to deploy downsized designs and high performance communication circuits without compromise.”

The HCR lineup is underpinned by Murata’s stable and reliable multi-source supply chain, ensuring automotive users have no concerns over supply, while its high temperature operating window and strong resistance to solder cracks guarantee long-term reliability. The components have already entered mass production and samples are available upon request. To learn more or to request samples, please contact your local Murata’s representative or visit here.

Please contact us for details: contact form

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113670074/en/

Contacts

For more information, please contact:
Murata Manufacturing Co., Ltd.
Keisuke Tsuboi
prsec_mmc@murata.com
Corporate Communications Department

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Emulate Energy and Smartcar Partner to Drive EV Utilization as Distributed Energy Resources14.11.2024 08:00:00 CET | Press Release

Emulate Energy, distributed energy resource management system (DERMS) software, today announced a partnership with Smartcar, the leading API platform for mobility businesses. By seamlessly integrating EVs into its platform, Emulate offers energy providers a comprehensive solution to simplify onboarding and management of different consumer distributed energy resources (DERs). This partnership enables energy providers using Emulate to use EV charging flexibility effectively as a way to balance the grid, reduce peak demand, and improve overall grid reliability. Enabling reliable EV integration for energy providers By expanding its EV support to a wider range of models, Emulate is enabling energy providers to harness the power of EVs as a valuable energy resource. Smartcar helps Emulate automate EV data retrieval to optimize charging schedules based on different pricing factors. Consumers can set their preferred charging preferences using the software and have peace of mind knowing Emulate

Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval14.11.2024 07:00:00 CET | Press Release

Curatis Holding (SIX:CURN) has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years. According to the US Public Health Service Act, the status of “biologic” is intended for peptides with a length of more than 40 amino acids. The molecule C-PTBE-01 has a length of 41 amino acids. The orphan drug designation for C-PTBE-01 will be pursued as planned. About C-PTBE-01 Curatis is focusing its development activities for C-PTBE-01 on an very rare group of aggressive brain tumours (Diffuse Midline Glioma, D

SBC Medical Group Holdings Inc. Reports Third Quarter 2024 Financial Results13.11.2024 22:59:00 CET | Press Release

SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Total revenues for the three months ended September 30, 2024 were $53 million, representing an increase of 12% from $47 million in the same quarter of 2023. Total revenues for the nine months ended September 30, 2024 was $160 million, representing an increase of 23% from $131 million in the same period of 2023. Income from operations for the three months ended September 30, 2024 was $13 million, representing a decrease by 31% from the same quarter in 2023. This result was impacted by $12.8 million of stock-based compensation expense related to the Company’s listing process. Income from operations for the nine months ended September 30, 2024 was $65.5 million, representing an increase o

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services13.11.2024 18:00:00 CET | Press Release

Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research. For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This

Medidata Secures Highest Leadership Position in Everest Group’s First Life Sciences Clinical Trial Management System Products PEAK Matrix ® Assessment13.11.2024 15:30:00 CET | Press Release

Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group's first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment 2024. The report assessed 13 providers based on the market impact of their products and their ability to deliver successful, high-quality offerings. Medidata Rave CTMS leads the industry by providing seamless, real-time patient data outputs that transform enrollment tracking and enable faster, data-driven decisions. Offering instant visibility for study teams, Rave CTMS streamlines collaboration, eliminates manual data entry, and accelerates trial timelines with exceptional accuracy. “We are honored to be recognized as the highest leader in CTMS by Everest Group,” said Tom Doyle, chief technology officer, Medidata. “This accolade underscores our unwavering commitment to transforming research and reaffirms our strategy to deliver

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye